Featured FCTDI Collaboration Partners (Past & Present)

• Biohaven Pharmaceuticals, Inc.
• Fox Chase Cancer Center
• Oligomerix, Inc.
• The Wistar Institute
• Vironika LLC
• ALS Biopharma
• University of Pennsylvania
• University of Pittsburgh
• New York Blood Center
• Rutgers University
• University of Florida
• Thomas Jefferson University
• Temple University
• University of Arizona
• Albert Einstein University

We interact with our research partners through a variety of funding mechanisms

SBIR/STTR Grants

• 20% Phase I funding rate
• 40% conversion rate to Phase II
• Inaccessible to academia

R01/U01 Grants

• FCTDI acts as a sub-awardee
• FCTDI prepares drug discovery description and plan needed for successful grant application

FTE Sponsored Research

• Industry standard methods
• Expert selection criteria
• Guaranteed FTE capacity with all essential equipment in world class facility

OUR MISSION

To assist our research partners in developing their fundamental research into bona-fide drug discovery programs through:

• Seek, find, and develop molecular probes to better elucidate the target and potential therapeutic application.
• Advance Hits from screening to Lead status, using in silico design and chemical synthesis via small, directed libraries or individual compounds; improve and develop structural activity relationships (SAR) as well as evaluate and improve ADME properties.
• Determine the intellectual property position of chemical matter and provide a path forward for which novel compositions can be prepared and protected.
• At FCTDI, our employees have over 150 years of industrial experience ranging from big pharma (J&J, GSK, Pfizer) to biotech and contract research organizations.
• A partial list of therapeutic areas and target classes investigated at FCTDI
  • Central nervous system, neurology, and psychiatry
  • Anti-infectives (antibacterial and antiviral)
  • Inflammation and immunology
  • Diabetes and obesity, multiple targets
  • GPCRs
  • Kinases

WATCH VIDEO

FCTDI provides medicinal chemistry, target validation, in vitro pharmacology, and chemical biology support to investigators at corporate collaboration partners, universities, and non-profit research organizations and foundations. Our goal is to transition innovative biomedical research technologies into full-fledged drug discovery and development programs of study.

FCTDI uses modern methods of medicinal chemistry, literature, searching and pharmacology. FCTDI scientists  also are deeply involved with the creation of new intellectual property and assist our partners in writing patent applications and the patent prosecution process. Ultimately, our measure of success is the ability to advance compounds into human clinical trials.